Health news and discussion on TalkFuse.
Alzheimer’s brain decline slashed in half by ‘thrilling’ new twice-a-year drug: trial
In a Phase 2 trial, people given low-dose diranersen had 54% less decline in memory and thinking over nearly two years. The experimental drug also reduced aggregated tau, a protein associated with Alzheimer’s-related brain cell damage, raising hopes that it could slow disease progression.
Diranersen is given by injection twice a year and uses gene-silencing technology to reduce the RNA messages that prompt brain cells to produce tau. Researchers said treatment was generally well tolerated, though side effects included lumbar-puncture pain, headaches and confusion, especially at higher doses. A larger Phase 3 trial is needed to confirm the results, and recruitment in the UK is expected to begin in spring.
In short
- Low-dose diranersen was linked to 54% less cognitive decline over nearly two years.
- The trial also found a reduction in aggregated tau.
- Phase 3 testing is needed to confirm the findings.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The trial offers a reason for cautious optimism: low-dose diranersen was associated with substantially less decline in memory and thinking, alongside reduced tau, a protein linked to Alzheimer’s-related cell damage. If larger trials confirm the effect, a treatment given twice a year could help slow progression and be manageable for patients, though the reported side effects and need for further evidence matter.
The case against
A Phase 2 result, even a promising one, cannot establish that diranersen will reliably slow Alzheimer’s or provide meaningful benefit in wider clinical use; the Phase 3 trial is still needed to confirm the findings. The treatment also involves injections and lumbar punctures, and reported pain, headaches and confusion—particularly at higher doses—leave questions about tolerability and the balance of benefit and burden.
Explained simply
Alzheimer’s disease is a progressive condition that affects memory, thinking and everyday life. It is linked to changes in the brain, including the build-up of tau, a protein that can damage brain cells.
Diranersen is an experimental treatment designed to reduce the instructions cells use to make tau. It is given by injection twice a year, and researchers are studying whether lowering tau can slow the disease.
The reported results come from a mid-stage trial, which tests a treatment in a limited number of people. A larger trial is needed to check whether the effects hold up and to learn more about possible side effects.